The global obesity epidemic continues to accelerate, with prevalence rising worldwide. Obesity is a key driver of cardiovascular risk factors—including dyslipidemia, type 2 diabetes, hypertension, and sleep disorders—and independently contributes to the development of cardiovascular disease (CVD) and related mortality.
In this webinar, we will explore recent advances in drug target discovery for fat loss and muscle preservation, highlighting key pathways such as GLP-1, INHBE, ACVR1C, Activin A Receptor Type 2 (ActRII), and Myostatin. We will also examine emerging therapeutic targets for cardiovascular disease, including Lipoprotein(a), PCSK9, and ANGPTL3.
In addition, we will showcase Biocytogen’s portfolio of humanized mouse models and disease models, designed to accelerate the development of next-generation therapies for metabolic and cardiovascular diseases.
Featured case studies include:
- In vivo drug efficacy studies in HFD-induced humanized GIPR, GLP1R, and GCGR mouse models
- Muscle preservation studies targeting ActRII and Myostatin
- Mouse models for lipid metabolism disorders
- In vivo drug efficacy studies in Western diet-induced humanized LPA, APOB, and PCSK9 mouse models
Speaker:
Jinyi Ma, Ph.D.
Product Manager, BioMice Metabolic & Neuroscience Department
Biocytogen
Panelist:
Hannah Horton, Ph.D.
Regional Director of Business Development
Biocytogen
Sha Qiao, Ph.D.
Manager & Principal Scientist, Disease Models
Pharmacology Department
Biocytogen
